Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group

Archives of Pathology and Laboratory Medicine

Volumn 137, Issue 5, 2013, Pages 647-667

  Husain, Aliya N ^a   Colby, Thomas ^b   Ordonez, Nelson ^c   Krausz, Thomas ^a   Attanoos, Richard ^d   Beasley, Mary Beth ^e   Borczuk, Alain C ^f   Butnor, Kelly ^g   Cagle, Philip T ^h   Chirieac, Lucian R ⁱ   Churg, Andrew ^j   Dacic, Sanja ^k   Fraire, Armando ^l   Galateau Salle, Francoise ^m   Gibbs, Allen ^d   Gown, Allen ⁿ   Hammar, Samuel ^o   Litzky, Leslie ^p   Marchevsky, Alberto M ^q   Nicholson, Andrew G ^r   Roggli, Victor ^s   Travis, William D ^t   Wick, Mark ^u   more..

^a UNIVERSITY OF CHICAGO   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d LLANDOUGH HOSPITAL   (United Kingdom)

^e MOUNT SINAI HOSPITAL   (United States)

^f NewYork Presbyterian Hospital   (United States)

^g UNIVERSITY OF VERMONT   (United States)

^h HOUSTON METHODIST HOSPITAL   (United States)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^k UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^l UNIVERSITY OF MASSACHUSETTS   (United States)

^m Laboratoire d'Anatomie Pathologique   (France)

ⁿ PHENOPATH LABORATORIES   (United States)

^o Diagnostic Specialties Laboratory Inc   (United States)

^p HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^q CEDARS SINAI MEDICAL CENTER   (United States)

^r ROYAL BROMPTON HOSPITAL   (United Kingdom)

^s DUKE UNIVERSITY MEDICAL CENTER   (United States)

^t MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^u UNIVERSITY OF VIRGINIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; CONSENSUS DEVELOPMENT; DIFFERENTIAL DIAGNOSIS; HUMAN; LUNG TUMOR; MESOTHELIOMA; PATHOLOGY; PLEURA TUMOR; PRACTICE GUIDELINE; REVIEW;

ADENOCARCINOMA; DIAGNOSIS, DIFFERENTIAL; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; PLEURAL NEOPLASMS;

EID: 84877984464     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2012-0214-OA     Document Type: Review

References (99)

1. Husain AN, Colby TV, Ordonez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med. 2009;133(8): 1317-1331.
2. Churg A, Colby TV, Cagle P, et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol. 2000;24(9):1183-1200.
3. Attanoos RL, Griffin A, Gibbs AR. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium: a novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and bcl-2. Histopathology. 2003;43(3): 231-238. (Pubitemid 37115056)
4. King J, Thatcher N, Pickering C, Hasleton P. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology. 2006;49(6):561-568. (Pubitemid 44924287)
5. Kato Y, Tsuta K, Seki K, et al. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol. 2007;20(2):215-220. (Pubitemid 46422176)
6. Acurio A, Arif Q, Gattuso P, et al. Value of immunohistochemical markers in differentiating benign from malignant mesothelial lesions. Mod Pathol. 2008; 21:334A. Abstract 1527.
7. Lagana S, Taub R, Borczuk A. Utility of glucose transporter 1 in the distinction of malignant thoracic and abdominal mesothelial lesions. Arch Pathol Lab Med. In press.
8. Shi M, Fraire AE, Chu P, et al. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation. Am J Surg Pathol. 2011;35(6):878-882.
9. Krismann M, Muller KM, Jaworska M, Johnen G. Pathological anatomy and molecular pathology. Lung Cancer. 2004;45(suppl 1):S29-S33. (Pubitemid 38917110)
10. Mangano WE, Cagle PT, Churg A, Vollmer RT, Roggli VL. The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: a histologic and immunohistochemical analysis of 31 cases including p53 immunostaining. Am J Clin Pathol. 1998;110(2):191-199. (Pubitemid 28357658)
11. Churg A, Cagle P, Colby TV, et al. The fake fat phenomenon in organizing pleuritis: A source of confusion with desmoplastic malignant mesotheliomas. Am J Surg Pathol. 2011;35(12):1823-1829.
12. Whitaker D. The cytology of malignant mesothelioma. Cytopathology. 2000;11(3):139-151. (Pubitemid 30409295)
13. Sheaff M. Should cytology be an acceptable means of diagnosing malignant mesothelioma? Cytopathology. 2011;22(1):3-4.
14. Au AY, Hackl T, Yeager TR, et al. Telomerase activity in pleural malignant mesotheliomas. Lung Cancer. 2011;73(3):283-288.
15. Ikeda K, Tate G, Suzuki T, Kitamura T, Mitsuya T. Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations. Diagn Cytopathol. 2011;39(6):395-401.
16. Ikeda K, Tate G, Suzuki T, Kitamura T, Mitsuya T. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology. Hum Pathol. 2010;41(5): 745-750.
17. Lonardi S, Manera C, Marucci R, Santoro A, Lorenzi L, Facchetti F. Usefulness of claudin 4 in the cytological diagnosis of serosal effusions. Diagn Cytopathol. 2011;39(5):313-317.
18. Illei PB, Rusch VW, Zakowski MF, Ladanyi M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res. 2003;9(6):2108-2113. (Pubitemid 36687632)
19. Illei PB, Ladanyi M, Rusch VW, Zakowski MF. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer. 2003;99(1):51-56. (Pubitemid 36267967)
20. Monaco SE, Shuai Y, Bansal M, Krasinskas AM, Dacic S. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. Am J Clin Pathol. 2011;135(4):619-627.
21. Kadota K, Suzuki K, Sima CS, Rusch VW, Adusumilli PS, Travis WD. Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma. J Thorac Oncol. 2011;6(5):896-904.
22. Pereira TC, Saad RS, Liu Y, Silverman JF. The diagnosis of malignancy in effusion cytology: a pattern recognition approach. Adv Anat Pathol. 2006;13(4): 174-184. (Pubitemid 44341653)
23. Kadota K, Suzuki K, Colovos C, et al. A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma. Mod Pathol. 2012;25(2):260-271.
24. Kawai T, Hiroi S, Nakanishi K, et al. Lymphohistiocytoid mesothelioma of the pleura. Pathol Int. 2010;60(8):566-574.
25. Travis WD. Sarcomatoid neoplasms of the lung and pleura. Arch Pathol Lab Med. 2010;134(11):1645-1658.
26. Allen TC. Recognition of histopathologic patterns of diffuse malignant mesothelioma in differential diagnosis of pleural biopsies. Arch Pathol Lab Med. 2005;129(11):1415-1420. (Pubitemid 41587016)
27. Cagle PT. Pleural histology. In: Light R, Lee YCG, eds. Pleural Disease: An International Textbook. London, United Kingdom: Arnold Publishers; 2003:249-255.
28. Cagle PT, Churg A. Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies. Arch Pathol Lab Med. 2005; 129(11):1421-1427. (Pubitemid 41587017)
29. Churg A, Roggli VL, Galateau-Salle F. Tumours of the pleura: mesothelial tumours. In: Travis WD, Brambilla E, Harris CC, Muller-Hermelink HK, eds. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC; 2004. World Health Organization Classification of Tumours; vol 10:128-136.
30. Churg A, Cagle PT, Roggli VL, eds. Tumors of the Serosal Membranes. Silver Spring, MD: ARP Press; 2006. Atlas of Tumor Pathology; 4th series, fascicle 3.
31. Galateau-Salle F, Brambilla E, Cagle PT. Classification and histologic features of mesothelioma. In: Galateau-Salle F, ed. Pathology of Malignant Mesothelioma. London, United Kingdom: Springer-Verlag; 2006:68-131.
32. Roggli VL, Cagle PT. Pleura, pericardium and peritoneum. In: Silverberg SG, DeLellis RA, Frable WJ, LiVolsi VA, Wick MR, eds. Silverberg's Principles and Practice of Surgical Pathology. 4th ed. New York, NY: Churchill-Livingstone/ Elsevier; 2006:1005-1039.
33. Ordonez NG. Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch Pathol Lab Med. 2005;129(11):1407-1414. (Pubitemid 41587015)
34. Cagle PT, ed. The Color Atlas and Text of Pulmonary Pathology. New York, NY: Lippincott Williams and Wilkins; 2005.
35. Weissferdt A, Kalhor N, Suster S. Malignant mesothelioma with prominent adenomatoid features: a clinicopathologic and immunohistochemical study of 10 cases. Ann Diagn Pathol. 2011;15(1):25-29.
36. Ordonez NG. Pleomorphic mesothelioma: report of 10 cases. Mod Pathol. 2012;25(7):1011-1022.
37. Dessy E, Falleni M, Braidotti P, Del Curto B, Panigalli T, Pietra GG. Unusual clear cell variant of epithelioid mesothelioma. Arch Pathol Lab Med. 2001; 125(12):1588-1590. (Pubitemid 33152056)
38. Ordonez NG, Mackay B. Glycogen-rich mesothelioma. Ultrastruct Pathol. 1999;23(6):401-406. (Pubitemid 30029877)
39. Ordonez NG, Myhre M, Mackay B. Clear cell mesothelioma. Ultrastruct Pathol. 1996;20(4):331-336. (Pubitemid 26274481)
40. Ordonez NG. Mesothelioma with clear cell features: an ultrastructural and immunohistochemical study of 20 cases. Hum Pathol. 2005;36(5):465-473. (Pubitemid 40775999)
41. Cook DS, Attanoos RL, Jalloh SS, Gibbs AR. "Mucin-positive" epithelial mesothelioma of the peritoneum: an unusual diagnostic pitfall. Histopathology. 2000;37(1):33-36. (Pubitemid 30496733)
42. Ordonez NG. Mesotheliomas with small cell features: report of eight cases. Mod Pathol. 2012;25(5):689-698.
43. Ordonez NG. Mesothelioma with rhabdoid features: an ultrastructural and immunohistochemical study of 10 cases. Mod Pathol. 2006;19(3):373-383. (Pubitemid 43276991)
44. Kiyozuka Y, Miyazaki H, Yoshizawa K, et al. An autopsy case of malignant mesothelioma with osseous and cartilaginous differentiation: bone morphogenetic protein-2 in mesothelial cells and its tumor. Dig Dis Sci. 1999;44(8):1626-1631. (Pubitemid 29434736)
45. Suen HC, Sudholt B, Anderson WM, Lakho MH, Daily BB. Malignant mesothelioma with osseous differentiation. Ann Thorac Surg. 2002;73(2):665. (Pubitemid 34117441)
46. Yousem SA, Hochholzer L. Malignant mesotheliomas with osseous and cartilaginous differentiation. Arch Pathol Lab Med. 1987;111(1):62-66. (Pubitemid 17144065)
47. Henderson DW, Attwood HD, Constance TJ, Shilkin KB, Steele RH. Lymphohistiocytoid mesothelioma: a rare lymphomatoid variant of predominantly sarcomatoid mesothelioma. Ultrastruct Pathol. 1988;12(4):367-384.
48. Khalidi HS, Medeiros LJ, Battifora H. Lymphohistiocytoid mesothelioma: an often misdiagnosed variant of sarcomatoid malignant mesothelioma. Am J Clin Pathol. 2000;113(5):649-654. (Pubitemid 33044304)
49. Klebe S, Mahar A, Henderson DW, Roggli VL. Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review. Mod Pathol. 2008;21(9):1084-1094.
50. Klabatsa A, Nicholson AG, Dulay K, Rudd RM, Sheaff MT. Diffuse pleural mesothelioma with epithelioid and angiosarcomatous components -a hitherto undescribed pattern of differentiation. Histopathology. 2012;60(7):1164-1166.
51. Baker PM, Clement PB, Young RH. Malignant peritoneal mesothelioma in women: a study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis. Am J Clin Pathol. 2005;123(5):724-737. (Pubitemid 40586490)
52. Kannerstein M, Churg J. Peritoneal mesothelioma. Hum Pathol. 1977;8(1): 83-94. (Pubitemid 8048350)
53. Sebbag G, Yan H, Shmookler BM, Chang D, Sugarbaker PH. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg. 2000;87(11): 1587-1593.
54. Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am. 2003; 12(3):605-621, xi. (Pubitemid 36920088)
55. Borczuk AC, Taub RN, Hesdorffer M, et al. P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma. Clin Cancer Res. 2005;11(9):3303-3308. (Pubitemid 40627879)
56. Goldblum J, Hart WR. Localized and diffuse mesotheliomas of the genital tract and peritoneum in women: a clinicopathologic study of nineteen true mesothelial neoplasms, other than adenomatoid tumors, multicystic mesotheliomas, and localized fibrous tumors. Am J Surg Pathol. 1995;19(10):1124-1137.
57. Malpica A, Sant'Ambrogio S, Deavers MT, Silva EG. Well-differentiated papillary mesothelioma of the female peritoneum: a clinicopathologic study of 26 cases. Am J Surg Pathol. 2012;36(1):117-127.
58. Butnor KJ, Sporn TA, Hammar SP, Roggli VL. Well-differentiated papillary mesothelioma. Am J Surg Pathol. 2001;25(10):1304-1309. (Pubitemid 32917125)
59. Daya D, McCaughey WT. Well-differentiated papillary mesothelioma of the peritoneum; a clinicopathologic study of 22 cases. Cancer. 1990;65(2):292-296. (Pubitemid 20035355)
60. Hammar SP, Bockus DE, Remington FL, Rohrbach KA. Mucin-positive epithelial mesotheliomas: a histochemical, immunohistochemical, and ultrastructural comparison with mucin-producing pulmonary adenocarcinomas. Ultrastruct Pathol. 1996;20(4):293-325. (Pubitemid 26274479)
61. Klebe S, Brownlee NA, Mahar A, et al. Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases. Mod Pathol. 2010;23(3):470-479.
62. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003;27(11):1418-1428. (Pubitemid 37315193)
63. Yaziji H, Battifora H, Barry TS, et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol. 2006;19(4):514-523.
64. Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 2010;41(1):20-25.
65. Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol. 2006;19(3):417-428. (Pubitemid 43276996)
66. Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. Hum Pathol. 2004;35(6):697-710. (Pubitemid 38881080)
67. Tacha D, Zhou D, Cheng L. Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. Appl Immunohistochem Mol Morphol. 2011;19(4):293-299.
68. Laury AR, Hornick JL, Perets R, et al. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol. 2010;34(5):627-635.
69. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88(2):358-363. (Pubitemid 30051820)
70. Comin CE, Saieva C. Messerini L. h-caldesmon, calretinin, estrogen receptor, and ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol. 2007;31(8):1139-1148. (Pubitemid 47207115)
71. Laury AR, Perets R, Piao H, et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol. 2011;35(6):816-826.
72. Mayall FG, Goddard H, Gibbs AR. The diagnostic implications of variable cytokeratin expression in mesotheliomas. J Pathol. 1993;170(2):165-168. (Pubitemid 23192369)
73. Chirieac LR, Pinkus GS, Pinkus JL, Godleski J, Sugarbaker DJ, Corson JM. The immunohistochemical characterization of sarcomatoid malignant mesothelioma of the pleura. Am J Cancer Res. 2011;1(1):14-24.
74. Chu AY, Litzky LA, Pasha TL, Acs G, Zhang PJ. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol. 2005;18(1):105-110. (Pubitemid 40128102)
75. Ordonez NG. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol. 2005;36(4):372-380. (Pubitemid 40591807)
76. Kung IT, Thallas V, Spencer EJ, Wilson SM. Expression of muscle actins in diffuse mesotheliomas. Hum Pathol. 1995;26(5):565-570.
77. Trupiano JK, Geisinger KR, Willingham MC, et al. Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol. 2004;17(4):476-481. (Pubitemid 41646604)
78. Attanoos RL, Dojcinov SD, Webb R, Gibbs AR. Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms. Histopathology. 2000;37(3):224-231.
79. Lucas DR, Pass HI, Madan SK, et al. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study. Histopathology. 2003;42(3):270-279. (Pubitemid 36356860)
80. Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43(7):668-672.
81. Prins JB, Williamson KA, Kamp MM, et al. The gene for the cyclindependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma. Int J Cancer. 1998;75(4):649-653. (Pubitemid 28094115)
82. Cheng JQ, Jhanwar SC, Klein WM, et al. P16 alterations and deletion mapping of 9p21-P22 in malignant mesothelioma. Cancer Res. 1994;54(21): 5547-5551.
83. Hirao T, Bueno R, Chen CJ, Gordon GJ, Heilig E, Kelsey KT. Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Carcinogenesis. 2002;23(7):1127-1130. (Pubitemid 34814769)
84. Singhal S, Wiewrodt R, Malden LD, et al. Gene expression profiling of malignant mesothelioma. Clin Cancer Res. 2003;9(8):3080-3097. (Pubitemid 36993271)
85. Lopez-Rios F, Chuai S, Flores R, et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res. 2006;66(6):2970-2979.
86. Chiosea S, Krasinskas A, Cagle PT, Mitchell KA, Zander DS, Dacic S. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol. 2008;21(6):742-747. (Pubitemid 351744840)
87. Pu RT, Sheng ZM, Michael CW, Rhode MG, Clark DP, O'Leary TJ. Methylation profiling of mesothelioma using real-time methylation-specific PCR: a pilot study. Diagn Cytopathol. 2007;35(8):498-502. (Pubitemid 47267512)
88. Savic S, Franco N, Grilli B, et al. Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology. Chest. 2010; 138(1):137-144.
89. Flores-Staino C, Darai-Ramqvist E, Dobra K, Hjerpe A. Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions. Lung Cancer. 2010;68(1):39-43.
90. Krasinskas AM, Bartlett DL, Cieply K, Dacic S. CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival. Mod Pathol. 2010;23(4):531-538.
91. Dacic S, Kothmaier H, Land S, et al. Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas. Virchows Arch. 2008;453(6):627-635.
92. Panani AD, Maliaga K, Babanaraki A, Bellenis I. Numerical abnormalities of chromosome 9 and p16CDKN2A gene deletion detected by FISH in non-small cell lung cancer. Anticancer Res. 2009;29(11):4483-4487.
93. Conway C, Beswick S, Elliott F, et al. Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma. Genes Chromosomes Cancer. 2010;49(5):425-438.
94. Mohseny AB, Tieken C, van der Velden PA, et al. Small deletions but not methylation underlie CDKN2A/p16 loss of expression in conventional osteosarcoma. Genes Chromosomes Cancer. 2010;49(12):1095-1103.
95. Begueret H, Galateau-Salle F, Guillou L, et al. Primary intrathoracic synovial sarcoma: a clinicopathologic study of 40 t(X;18)-positive cases from the French Sarcoma Group and the Mesopath Group. Am J Surg Pathol. 2005;29(3): 339-346. (Pubitemid 40321969)
96. Weinbreck N, Vignaud JM, Begueret H, et al. SYT-SSX fusion is absent in sarcomatoid mesothelioma allowing its distinction from synovial sarcoma of the pleura. Mod Pathol. 2007;20(6):617-621. (Pubitemid 46788868)
97. Hammar SP. Macroscopic, histologic, histochemical, immunohistochemical, and ultrastructural features of mesothelioma. Ultrastruct Pathol. 2006;30(1): 3-17.
98. Dardick I, Al-Jabi M, McCaugheyWT, Srigley JR, van Nostrand AW, Ritchie AC. Ultrastructure of poorly differentiated diffuse epithelial mesotheliomas. Ultrastruct Pathol. 1984;7(2-3):151-160. (Pubitemid 15075667)
99. Dardick I, Jabi M, McCaughey WT, Deodhare S, van Nostrand AW, Srigley Jr. Diffuse epithelial mesothelioma: a review of the ultrastructural spectrum. Ultrastruct Pathol. 1987;11(5-6):503-533. (Pubitemid 18004384)